Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔 Read more
10.78
+0.01
+0.09%
- Morningstar Rating:
- Total Assets: 1.13B
Aspiriant Defensive Allocation
10.78
+0.01
+0.09%
- Overview
- Profile
- Historical Data
- Holdings
Aspiriant Defensive Allocation Fund Overview
On this page you'll find an in-depth profile of Aspiriant Defensive Allocation Fund. Learn about the key management, total assets, investment strategy and contact information of RMDFX among other information.
Investment Strategy
The investment seeks to achieve long-term investment returns with lower risk and lower volatility than the stock market, and with relatively low correlation to stock and bond market indexes. The fund is a "fund-of-funds" that seeks to provide an investment return that has lower volatility than traditional asset classes (i.e., public equity and investment grade bonds) by combining several non-traditional or alternative asset class exposures, including investments that focus on a specialized asset class such as long-short strategies. It is non-diversified.
Contact Information
Address
235 West Galena Street
Milwaukee,WI 53212
United States
Milwaukee,WI 53212
United States
Phone
1-877-997-9971
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| John Allen | CIO (Chief Investment Officer) | 2015 | Now |
| Biography | John Allen, CFA, CAIA, is Chief Investment Officer (“CIO”) at Aspiriant, LLC. Mr. Allen joined Aspiriant, LLC as CIO in 2014. Prior to joining Aspiriant, LLC he was a senior member of the client service team at Grantham, Mayo, Van Otterloo (“GMO”) from 2009 to 2014. Prior to joining GMO, Mr. Allen was Head of Investments at a large family office. He began working in the financial services industry in the investment banking department at Donaldson, Lufkin & Jenrette and business consulting practice of Stern Stewart & Company. | ||
| Marc Castellani | Managing Director | 2015 | Now |
| Biography | Marc Castellani, CFA, CAIA, CIMA, is Managing Director of Investment Strategy & Research at Aspiriant, LLC. Mr. Castellani joined Aspiriant, LLC in 2015. Prior to joining Aspiriant, LLC, he worked at J.P. Morgan Private Bank in Los Angeles from 2012 to 2015. Prior to joining J.P. Morgan Private Bank, he worked at U.S. Trust from 2010 to 2012. Previously, Mr. Castellani worked in Merger and Acquisitions of J.P. Morgan and Banc of America Securities. He began his career in the financial services industry as an Associate in the corporate finance advisory practice of Stern Stewart & Company. | ||
| David Grecsek | Managing Director | 2015 | 2020 |
| Biography | David Grecsek, CFA, is Managing Director of Investment Strategy & Research at Aspiriant, LLC. Mr. Grecsek joined Aspiriant, LLC in 2010. Prior to joining the Adviser, he was Head of Investment Research at Deloitte Investment Advisors. Previously, Mr. Grecsek worked in various investment research and risk management roles at Merrill Lynch & Co. | ||
Write your thoughts about Aspiriant Defensive Allocation Fund
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review